SCHEMBL23326902

SCHEMBL23326902

CCN(CC)CCNCc1ccc(N)c(C)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SKP2 Q13309 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.43
S100B P04271 1/20 0.42
ALDH1A1 P00352 3/20 0.38
KDM4E B2RXH2 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 2/20 0.36
USP2 O75604 1/20 0.36
LMNA P02545 3/20 0.36
TSHR P16473 2/20 0.36
SLC22A2 O15244 1/20 0.36
SLC22A1 O15245 1/20 0.36
ACHE P22303 1/20 0.36
MAPK1 P28482 1/20 0.36
CYP2C19 P33261 1/20 0.36
DRD4 P21917 1/20 0.36
BLM P54132 1/20 0.35
PMP22 Q01453 1/20 0.35
CYP3A4 P08684 1/20 0.35
TDP1 Q9NUW8 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16250560 0.79 LMNA (0.51) SMN1; SMN2ALDH1A1KDM4EHPGDHTT
SCHEMBL23327047 0.76 MAPT (0.42) SMN1; SMN2ALDH1A1KDM4EHPGDLMNA
SCHEMBL27707407 0.75 SKP2 (0.55) SKP2S100BALDH1A1TSHRACHE
SCHEMBL18768835 0.75 SIGMAR1 (0.55) SMN1; SMN2KDM4EHTTUSP2LMNA
SCHEMBL3456630 0.75 HRH3 (0.45) SMN1; SMN2HTTUSP2MEN1KMT2A
SCHEMBL2237413 0.75 NOS1 (0.51) SMN1; SMN2ALDH1A1KDM4EHTTUSP2
SCHEMBL6364808 0.74 CYP1A2 (0.61) SMN1; SMN2KDM4EHTTLMNATSHR
SCHEMBL3457092 0.73 CHRM2 (0.51) SMN1; SMN2KDM4EHTTUSP2MEN1
SCHEMBL1724753 0.72 SMN1; SMN2 (0.59) SMN1; SMN2KDM4EHTTUSP2LMNA
SCHEMBL16389697 0.72 MEN1 (0.46) SMN1; SMN2ALDH1A1KDM4EHPGDHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11427542-B2 Compounds for treatment of cardiac arrhythmias and heart failure ELEX BIOTECH, INC. (US) 2022-08-30 US claimed
US-20210139429-A1 COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE ELEX BIOTECH, INC. (US) 2021-05-13 US claimed
CN-111936466-A Compounds for the treatment of cardiac arrhythmias and heart failure 埃利克斯生物技术公司 2020-11-13 CN claimed
US-11427542-B2 Compounds for treatment of cardiac arrhythmias and heart failure ELEX BIOTECH, INC. (US) 2022-08-30 US disclosed
US-20210139429-A1 COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE ELEX BIOTECH, INC. (US) 2021-05-13 US disclosed
CN-111936466-A Compounds for the treatment of cardiac arrhythmias and heart failure 埃利克斯生物技术公司 2020-11-13 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210139429-A1 COMPOUNDS FOR TREATMENT OF CARDIAC ARRHYTHMIAS AND HEART FAILURE RYR2, RYR1, CACNA1F SKP2 1972/4885SMN1; SMN2 2063/4885S100B 979/4885
US-11427542-B2 Compounds for treatment of cardiac arrhythmias and heart failure RYR2, RYR1, CACNA1F SKP2 1972/4885SMN1; SMN2 2063/4885S100B 979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.